BioCorRx Inc. (BICX)

OTCMKTS: BICX · Delayed Price · USD
1.470
0.00 (0.00%)
Apr 16, 2024, 1:00 PM EDT - Market closed
Market Cap 9.26M
Revenue (ttm) 89,160
Net Income (ttm) -3.77M
Shares Out 8.82M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 200
Open 1.470
Previous Close 1.470
Day's Range 1.470 - 1.470
52-Week Range 0.672 - 2.220
Beta 0.85
Analysts n/a
Price Target n/a
Earnings Date Mar 29, 2023

About BICX

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The... [Read more]

Sector Healthcare
CEO Ms. Lourdes Felix
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol BICX
Full Company Profile

Financial Performance

In 2023, BioCorRx's revenue was $89,160, a decrease of -58.31% compared to the previous year's $213,841. Losses were -$3.77 million, -13.79% less than in 2022.

Financial Statements

News

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia

ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, ...

16 days ago - GlobeNewsWire

BioCorRx Reports Business Update for 2023

ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relate...

17 days ago - GlobeNewsWire

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD

ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related d...

7 weeks ago - GlobeNewsWire

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors

ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related...

2 months ago - GlobeNewsWire

BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President

ANAHEIM, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related...

3 months ago - GlobeNewsWire

BioCorRx Reports Business Update for the Third Quarter of 2023

ANAHEIM, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related...

5 months ago - GlobeNewsWire

BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder

Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis ANAHEIM, CA, Aug. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. ...

8 months ago - GlobeNewsWire

BioCorRx Reports Business Update for the Second Quarter of 2023

On Track to Meet 2023 Regulatory Milestones ANAHEIM, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatm...

8 months ago - GlobeNewsWire

BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder

ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related...

9 months ago - GlobeNewsWire

BioCorRx Provides Business Update for the First Quarter of 2023

Revenue Increases 97% ANAHEIM, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substa...

1 year ago - GlobeNewsWire

BioCorRx Provides Business Update for 2022

Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics

1 year ago - GlobeNewsWire

BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting

ANAHEIM, CA, March 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB:  BICX) (the “Company”), a clinical-stage developer and provider of innovative treatment programs for substance ...

1 year ago - GlobeNewsWire

BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data

ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related d...

1 year ago - GlobeNewsWire

BioCorRx to Present at Sequire Biotechnology Conference on February 2nd

Presentation on Thursday, February 2, 2023 at 2:00 PM ET

1 year ago - GlobeNewsWire

BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors

ANAHEIM, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via  NewMediaWire  -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and relate...

1 year ago - GlobeNewsWire

BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related d...

1 year ago - GlobeNewsWire

BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

ANAHEIM, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire   --   BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and r...

1 year ago - GlobeNewsWire

BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.

ANAHEIM, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relate...

1 year ago - GlobeNewsWire

BioCorRx Provides Business Update for the Third Quarter of 2022

ANAHEIM, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relate...

1 year ago - GlobeNewsWire

BioCorRx to Present at the LD Micro Main Event XV on October 25th

Anaheim, California--(Newsfile Corp. - October 24, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disord...

1 year ago - Newsfile Corp

BioCorRx to Participate at the LD Micro Main Event XV

Anaheim, California--(Newsfile Corp. - October 20, 2022) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related disord...

1 year ago - Newsfile Corp

BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related...

1 year ago - GlobeNewsWire

BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and relate...

1 year ago - GlobeNewsWire

BioCorRx Provides Business Update for the Second Quarter of 2022

ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related...

1 year ago - GlobeNewsWire

BioCorRx to Participate in the Benzinga All Access Event on July 15th

ANAHEIM, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related...

1 year ago - GlobeNewsWire